our
companymanagement
Robert Radie
President and Chief Executive Officer
Robert Radie joined TransMolecular in March 2009. Most recently, Mr. Radie was Executive Vice President and Chief Business Officer at Prestwick Pharmaceuticals, Inc. and Vice President of Project Management and Chief Business Officer at Morphotek. He played leading roles in the acquisition of Prestwick by Biovail in September 2008 and Morphotek by Eisai in 2007 and delivered premium shareholder returns for these transactions. In addition, he held the position of Senior Vice President of Strategic Projects and Planning at Vicuron Pharmaceuticals, where he was responsible for corporate strategy and business development. There he also played an integral role in the Pfizer acquisition of Vicuron in September 2005. Before joining Vicuron, Mr. Radie spent his professional career in a broad range of positions of increasing responsibility at Eli Lilly and Co. His tenure at Lilly was marked by leadership of several different sales forces and product launches, including the deployment of Lilly's Critical Care sales organization. He played a significant role in the launch and sales of many of Lilly's flagship products, including Prozac, Zyprexa, and Actos. He holds a Bachelor of Science degree in chemistry from Boston College.
Jonathan Lloyd Jones
Vice President of Finance
Jonathan Lloyd Jones joined TransMolecular in March 2006 and is responsible for the company's financial and controllership functions, information technology and operations management. He brings more than 20 years of financial management, accounting and business development experience to the company. Mr. Lloyd Jones joined TransMolecular from Genzyme where he was Senior Director of Corporate Development. At Genzyme, he was responsible for negotiating multi-million dollar acquisition and in-licensing opportunities, as well as sourcing opportunities, leading corporate due diligence efforts, and executing valuation and market analysis on major investments, including Sangstat, Geltex and Biomatrix. Mr. Lloyd Jones developed Genzyme's Opportunity Analysis Process for conducting due diligence and valuation exercises. At various times he headed Genzyme's Business Analysis, Valuation & Modeling and Commercial Assessment groups. Prior to his tenure with Genzyme, Mr. Lloyd Jones was Manager of Operations and Finance at The Royal Bank of Scotland (Nassau) Ltd. a registered Private Bank and Trust Company within The Royal Bank of Scotland Group. In this position, he was responsible for all financial, management and regulatory reporting, banking operations and information technology. From 1981 to 1986, Mr. Lloyd Jones was a senior auditor for member firms of Ernst & Young and Deloitte Touche Tohmatsu.
Mr. Lloyd Jones has been an invited speaker at the Regulatory Affairs Professionals Society and Food And Drug Law Institute and BIO 2000.
He is a Chartered Accountant and holds a M.B.A. with a dual major in strategic management and finance from The Wharton School at the University of Pennsylvania and a B.S. in business studies from The University of Bradford in England.
Douglas Jacoby, Ph.D.
Vice President of Research
Dr. Jacoby joined TransMolecular in November 2005. He is responsible for identifying new cancer opportunities using pre-clinical models and discovering new cancer drug mechanisms of TM-601, a synthetic version of chlorotoxin. Dr. Jacoby brings more than 12 years of research and development experience in oncology, cellular and molecular therapies. From 2003 to 2005, he held the position of Director of Research at GenVec, Inc. In this role, he worked on the company's oncology program to demonstrate biological activity of treatment and determine the mechanism of action in animal models and patients. From 1999 to 2003, Dr. Jacoby was the Director of Research at Diacrin. His research background includes successful translation of product candidates into clinical studies in the areas of neurodegenerative diseases, stroke, spinal cord injury and heart failure.
Dr. Jacoby earned an A.B. in biology from Kenyon College and received his Ph.D. in biochemistry from the University of Minnesota.